Abstract: The present invention concerns compounds of general formula (1), where in:—-a- is a single or double bond, Ar is an aromatic group, substituted or unsubstituted, R1 and R2 each independently or together are: a hydrogen atom or C1-C6 alkyl group, branched or unbranched, saturated or unsaturated, substituted or unsubstituted; the groups R1 and R2 may also form a heterocycle, R3 and R3? each independently or together are a hydrogen atom or C1-C6 alkyl group, X is an oxygen atom or a sulphur atom, and the addition salts of the compounds of general formula (1) with pharmaceutically acceptable mineral acids or organic acids.

Abstract: The present invention concerns compounds of general formula (1), where in:—-a- is a single or double bond, Ar is an aromatic group, substituted or unsubstituted, R1 and R2 each independently or together are: a hydrogen atom or C1-C6 alkyl group, branched or unbranched, saturated or unsaturated, substituted or unsubstituted; the groups R1 and R2 may also form a heterocycle, R3 and R3? each independently or together are a hydrogen atom or C1-C6 alkyl group, X is an oxygen atom or a sulphur atom, and the addition salts of the compounds of general formula (1) with pharmaceutically acceptable mineral acids or organic acids.

Abstract: The invention relates to a process for the preparation of compounds of general formula (3) wherein: (a) represents a single or double bond; W represents a group CH, CH2, CHCH3, CCH3, C(CH3)2, a group C(CH2)2 (i.e. a carbon atom carrying two methylene groups bonded to one another so as to form a spiro-cyclopropane moiety), with the proviso, however, that when (a) is a double bond then W represents exclusively a group CH or CCH3 and when (a) is a single bond then W represents exclusively a group CH2, CHCH3, C(CH3)2 or C(CH2)2.

Abstract: The invention provides compounds of the formula: wherein (a) is a single or double bond; W is CH, CH2, CHCH3, C(CH3)2, C(CH2)2 or C(CH2)3; X is N; and Y is H or F, and salts, hydrates, tautomers, pure enantiomers, and enantiomeric mixtures; and a method of treating schizophrenia comprising administering same.

Abstract: The invention provides compounds of the formula: wherein (a) is a single or double bond; W is CH, CH2, CHCH3, CCH3, C(CH3)2, C(CH2)2 or C(CH2)3, provided that when (a) is a double bond, then W is CH or CCH3, and when (a) is a single bond, then W is CH2, CHCH3, C(CH3)2, C(CH2)2 or C(CH2)3; X is CH or N; and Y is H or F, and salts, hydrates, tautomers, pure enantiomers, and enantiomeric mixtures; and a method of treating schizophrenia comprising administering same.

Abstract: The invention provides compounds of the formula wherein (a) is a single or double bond; W is CH, CH2, CHCH3, C(CH3)2, C(CH2)2 or C(CH2)3; X is N; and Y is H or F, and salts, hydrates, tautomers, pure enantiomers, and enantiomeric mixtures; and a method of treating schizophrenia comprising administering same.

Abstract: The invention provides compounds of the formula: wherein (a) is a single or double bond; W is CH, CH2, CHCH3, CCH3, C(CH3)2, C(CH2)2 or C(CH2)3, provided that when (a) is a double bond, then W is CH or CCH3, and when (a) is a single bond, then W is CH2, CHCH3, C(CH3)2, C(CH2)2 or C(CH2)3; X is CH or N; and Y is H or F, and salts, hydrates, tautomers, pure enantiomers, and enantiomeric mixtures; and a method of treating schizophrenia comprising administering same.

Abstract: The present invention relates to novel [(2-substituted-5-[3-thienyl])-benzyl]-[2-([2-isopropoxy-5-fluoro]-phenoxy)-ethyl]-amine derivatives having formula (1) and the use thereof as medicaments, especially anti-psychotic medicaments.

Abstract: The present invention relates to novel 3-alkoxybenzylamine derivatives of general formula (1): which are useful as medicinal products and in particular as antipsychotic agents.